Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Luu, Jennifer
NCT05275868: Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer	Recruiting	1	140	Europe, Japan, US, RoW	MGY825	Novartis Pharmaceuticals	Non-small Cell Lung Cancer	07/27	07/27
LEADER, NCT04712877: Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers	Recruiting	N/A	1000	US	ctDNA, tumor NGS, FoundationOne CDx, FoundationOne Liquid	Lung Cancer Mutation Consortium, Lung Cancer Research Foundation	NSCLC	06/25	06/26
Hoseth, Jennifer
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.	Recruiting	3	450	Europe, Canada, Japan, US, RoW	AAA617, (177Lu) vipivotide tetraxetan	Novartis Pharmaceuticals	Oligometastatic Prostate Cancer (OMPC)	12/27	07/30
NCT06562192: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers	Recruiting	1	124	Canada, US, RoW	[68Ga]Ga-NNS309, [177Lu]Lu-NNS309	Novartis Pharmaceuticals	Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer	06/30	06/30
Olegario, Justine
NCT05275868: Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer	Recruiting	1	140	Europe, Japan, US, RoW	MGY825	Novartis Pharmaceuticals	Non-small Cell Lung Cancer	07/27	07/27